MedTrace Logo

Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

NCT05540028 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2023-08-30

No results posted yet for this study

Summary

A first-in-human, Phase 1 trial to evaluate safety, tolerability, and immunogenicity of Inventprise's (IVT) 25-valent pneumococcal conjugate vaccine (IVT PCV-25)

Conditions

  • Pneumococcal Vaccines

Interventions

BIOLOGICAL

IVT PCV-25

25 valent pneumococcal conjugate vaccine

BIOLOGICAL

PCV 20

20 valent pneumococcal conjugate vaccine

Sponsors & Collaborators

  • Canadian Center for Vaccinology

    collaborator OTHER

  • Vaccine Evaluation Center, Canada

    collaborator OTHER

  • PATH

    collaborator OTHER

  • Inventprise Inc.

    lead INDUSTRY

Principal Investigators

  • Joanne Langley, MD, MSc, FRCPC · Canadian Center for Vaccinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-28
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05540028 on ClinicalTrials.gov